Posted by Michael Wonder on 27 Mar 2023
Incyte announces Japanese approval of Pemazyre (pemigatinib) for the treatment of patients with myeloid/lymphoid neoplasms
27 March 2023 - Incyte today announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor inhibitor, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion (also known as 8p11 myeloproliferative syndrome).
Myeloid/lymphoid neoplasms are a rare, aggressive group of cancers characterised by an over-production of myeloid cells, or bone tissue, with the tendency to rapidly progress to an acute myeloid leukaemia.
